



EDUCATION DAY PRELIMINARY PROGRAM

TRANSFORMING CLINICAL TRIALS IN THE MODERN-DAY ERA Education Day Chairs: Brian Alexander, Ingo Mellinghoff, Joohee Sul, Martin Taphoorn		
8:00am – 8:10am	Welcome and Introduction	
8:10am – 8:40am	Keynote: Global view of cancer	Ronald DePinho
8:40am – 10:15am	Session 1 – Cancer Biology and Genomics Session Chair: Ingo Mellinghoff We are currently in an era of rapid advancement in our understanding of the genomic, molecular, immunologic and biologic basis of carcinogenesis. How have these advances impacted the field of neuro-oncology? How do we decide which therapies to evaluate in which patient populations? Which biomarkers should we assess and how? In this session, we will discuss rational selection of targets, biomarkers, and anti-tumor agents for clinical trials.	
8:40am – 9:00am	Aberrant Signaling in Brain Tumors	Ingo Mellinghoff
9:00am – 9:20am	Molecular Trajectories of Glioma	Roel Verhaak
9:20am – 9:40am	Modeling Brain Tumor Development	Suzanne Baker
9:40am – 10:00am	Harnessing “Big Data”	Nikolaus Schultz
10:00am – 10:15am	Panel Discussion	
10:15am – 10:30am	BREAK	
10:30am – 12:05pm	Session 2 – Clinical Trials Basics Session Chair: Joohee Sul In this session, we will review and discuss basic principles of clinical trials, and important considerations for trial design and endpoints. This session will be primarily targeted for junior and young investigators, as well as those looking to review clinical trials basics.	
10:30am – 10:50am	Clinical Trials 101	Jennifer Clarke
10:50am – 11:10am	Designs for Small Patient Populations	Karla Ballman
11:10am – 11:30am	Endpoints for Clinical Trials	Joohee Sul
11:30am – 11:50am	Pitfalls in Oncology Drug Development	Patrick Wen
11:50am – 12:05pm	Panel Discussion	
12:05pm – 1:05pm	LUNCH	

1:05pm – 1:35pm	Keynote: Novel Precision Medicine Trial Designs- Oncology Center of Excellence Perspectives	Gideon Blumenthal
1:35pm – 3:45pm	Session 3 – Next-generation trials and biomarkers Session Chairs: Ingo Mellinghoff, Joohee Sul In the past, “classic” phase I, II and III studies generally evaluated single agents in discrete diseases and assessed standard endpoints such as MTD and survival. Clinical trial designs have evolved over the past decade, and newer strategies such as global “platform” trials (e.g. master protocols, basket trials), seamless designs and adaptive approaches have led to more efficient evaluation of drugs and targets. In this session, we will discuss the changing paradigm for clinical trials in oncology. How and when should we assess biomarkers? How may these newer approaches be applied to investigate products to treat brain tumors? How do we maintain statistical rigor and integrity?	
1:35pm – 1:55pm	Methylation Signatures	Stefan Pfister
1:55pm – 2:15pm	Standardization and Implementation of Imaging Biomarkers in Glioma Multicenter Clinical Trials	Benjamin Ellingson
2:15pm – 2:35pm	Digital Technology: Digital Biomarkers, Outcomes, and Performance Measures	Andrea Coravos
2:35pm – 2:55pm	Novel Clinical Trial Designs	Howard Colman
2:55pm – 3:15pm	Perspectives from Pharma	Lauren Abrey
3:15pm – 3:30pm	Panel Discussion	
3:30pm – 3:45pm	BREAK	
3:45pm – 5:00pm	Session 4 – Improving patient participation in clinical trials Session Chair: Martin Taphoorn We are all familiar with the statistic that < 2% of patients diagnosed with cancer participate in clinical trials in the US. Yet patient involvement is essential to the successful conduct of any clinical trial. In this session, we discuss the barriers to enrolling patients on neuro-oncology trials. What strategies have been employed to improve access to clinical trials in other diseases? How can we use clinical outcomes assessments to measure what matters for patients?	
3:45pm – 4:05pm	Practitioners views on clinical trials-survey results	Terri Armstrong
4:05pm – 4:25pm	Access to Trials-The BTN Experience	Kay Verble
4:25pm – 4:45pm	Clinical outcomes assessments/RANO COA	Martin Taphoorn
5:45pm – 5:00pm	Panel Discussion	All of the above, plus Liz Salmi, David Jenkinson, David Arons
5:00pm	ADJOURN	